BPC-157 and Gym Peptides: The Evidence and the Risks

Published October 12, 2026

Collage of three small unlabeled glass vials next to a hex dumbbell, with the headline "BPC-157: The Evidence"

BPC-157 looks promising in rats and rabbits, but there is almost no human evidence that it heals tendons or joints, no known safe dose, no approval from the FDA or any other health authority, and a ban in drug-tested sport. If a tendon or joint hurts, progressive loading, ideally guided by a good physical therapist, has far better evidence behind it than a peptide of unknown contents.

This article is general education, not medical advice. It does not explain how to use, source or dose any drug or peptide, and it never will. If you are in pain, injured, or thinking about injecting anything, talk to a doctor or physical therapist who can examine you.

What BPC-157 is

BPC-157 is a chain of 15 amino acids, short enough to be called a peptide. The name stands for Body Protection Compound, a label given to a substance isolated from human gastric juice for its apparent protective effects. BPC-157 is a fragment of it. Researchers at the University of Zagreb in Croatia first synthesized and studied it in the early 1990s, according to the FDA's own review.

It is not a vitamin, a protein powder or an approved medicine. In the US it sits in a gray zone: sold online under research-use-only labels, offered by some clinics, and promoted by podcasters for tendon, joint and gut healing. "Gym peptides" also covers other injectables with their own evidence profiles. This article covers BPC-157 only.

What the animal evidence shows

The case for BPC-157 comes almost entirely from animals. A 2025 systematic review in the HSS Journal (Vasireddi et al.) searched the literature through June 2024 for BPC-157 in orthopaedic sports medicine. It identified 544 articles and, after screening, kept 36. Thirty-five were preclinical, with work in animals such as rats and rabbits, and only one involved people. In the animal models of muscle, tendon and ligament injury that the review describes, treated animals generally showed better functional, structural and mechanical outcomes. The proposed mechanisms include more blood vessel growth, nitric oxide signalling and lower inflammatory markers.

That is a reason to run human trials, not a reason to inject it. Two limits matter:

Concentrated sources. A February 2026 Undark report (Sara Talpos, co-published with STAT) reports that almost all existing data on BPC-157 comes from a single group of researchers in Croatia, and that one of them, University of Zagreb pharmacologist Predrag Sikiric, has published more than 150 papers on it. Findings that have not been repeated by independent labs are weaker than they look.
Different injuries and bodies. An induced injury in a laboratory animal is not a patellar tendon irritated for two years by squatting, and a regimen that worked in a rat says little about what is safe or useful in a person.

Sports-medicine physicians have noticed the pattern. In a spring 2026 AOSSM newsletter article on peptides (Reese, Wagner and Ellis), the authors say these peptides share one trajectory: "promising animal data with no evidence of efficacy in humans."

What the human evidence shows

The HSS Journal review found one clinical study among its 544 hits: a retrospective look at injections into the knee for chronic knee pain, in which 7 of 12 patients reported relief lasting more than six months. With 12 people, no control group and a retrospective design, that cannot separate a drug effect from placebo response or the normal ups and downs of chronic pain. The review's authors state that they found no clinical safety data and advise caution.

Other reviewers agree. A 2025 narrative review (McGuire et al., Current Reviews in Musculoskeletal Medicine) found only three published human studies and called BPC-157 investigational until well-designed human trials exist.

The FDA's own staff reached a similar view in a briefing document for its July 2026 advisory committee meeting. They found five small clinical studies that used BPC-157, which were short, used doses that were likely exploratory, and had safety monitoring that was unclear for most of them. They found no studies that gave it to humans by the oral, under-the-skin, nasal or skin-cream routes proposed for compounding, no human data on how the body absorbs and clears it by those routes, and no study that formally investigated whether it triggers immune responses. A registered phase 1 trial had no posted results and no matching publication.

What would settle the question is a randomized, placebo-controlled trial in a defined tendon injury, with the product independently verified and follow-up long enough to catch problems. None of the reviews above found one.

Safety: what is unknown and what has been reported

Small trials reported no serious adverse events, which sounds reassuring until you read the fine print. The FDA reviewers noted that those studies were small and short. A clean record in a small group of people over a couple of weeks at most does not tell you what happens over months in thousands of people.

Immune reactions. FDA staff flagged immunogenicity as a core concern. Peptides given by injection or nasal spray can provoke immune responses, from antibodies with no apparent symptoms to life-threatening reactions, and impurities or clumped (aggregated) product can amplify the risk. They found no study that formally investigated this for BPC-157 products.
Adverse event reports. The FDA staff briefing found three reports in the agency's adverse event database through December 2025, all involving injected BPC-157: an injection-site reaction, shortness of breath, and skin and gum darkening. Whether the peptide caused them is unclear, and the agency said it cannot draw definitive conclusions about safety from those reports alone.
A theoretical worry. Because the proposed mechanism involves growing new blood vessels, McGuire and colleagues raise a theoretical concern about unwanted blood vessel growth. They also cite animal data pointing the other way. Nobody has studied long-term human use, so the question is open.

Then there is the product itself. In the Undark report, USADA's Matthew Fedoruk warns that with underground products you do not know what is inside the bottle, which could be a different drug or just water, and that people risk injecting something quite dangerous. In an AJMC interview after the committee vote, obesity-medicine physician Catherine Varney described serious cardiovascular events with one other peptide, MK-677, and gray-market products containing only 5 to 75 percent of the labeled amount, some with toxic impurities. The Operation Supplement Safety program notes that some products carry not-for-human-consumption disclaimers. A label on an unregulated vial is not a quality guarantee, and none of the animal or human data apply to an unknown mixture.

Legal status and drug-testing rules

BPC-157 is not an approved drug. USADA states that neither the FDA nor any other global health authority has approved it, that there are no human clinical trials establishing efficacy for any diagnosis, and that it is unknown whether a safe dose exists.

For athletes, it is prohibited under the S0 non-approved substances category of the WADA list. Sport Integrity Canada confirmed in April 2026 that it remains on the 2026 list and that use, administration, trafficking or possession could be an anti-doping rule violation. USADA says therapeutic use exemptions are unlikely because approved alternatives exist. If you compete in a tested federation, check its rules before you touch any peptide.

The compounding picture changed during 2026, and it is easy to misread:

As of the February 2026 Undark report, the FDA did not allow compounding pharmacies to supply BPC-157, citing potential significant safety risks.
By April 2026, AJMC reports, the agency had taken BPC-157 off its Category 2 restricted list.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding it to the list of substances pharmacies may compound. FDA staff had recommended against, citing a lack of evidence of effectiveness. Their review evaluated the proposed use for ulcerative colitis and did not evaluate tendonitis, because the nomination lacked enough information. RAPS reported that some panelists raised concerns about missing efficacy data and too many unknowns.

That vote is advice, not a final decision, and it is not a finding that the peptide works. A pharmacy being allowed to mix a substance is a different question from whether the substance was shown to help. This area was moving quickly, so check the FDA's compounding pages for the current status before relying on any of this.

What to do instead for a sore tendon or joint

Many tendon problems in lifters are linked to load: too much, too fast, or too little capacity for the demands. The approach with trial support is not a drug. It is progressive strength work, ideally guided by someone who has examined you.

1. Get the diagnosis right

Pain at the front of the knee, the back of the heel or the outside of the elbow can come from tendons, joints, bursae or nerves. A physical therapist or sports-medicine doctor can tell them apart, which decides what kind of loading helps. Check the red flags below before you start any plan.

2. Keep loading it, in a controlled way

In a 2015 randomized trial (Beyer et al., American Journal of Sports Medicine), 58 people with long-standing Achilles tendinopathy were assigned to 12 weeks of either heavy slow resistance training or eccentric-only training. Both groups improved in symptoms and function, the gains held at the 52-week follow-up, and the groups did not differ on those outcomes. Satisfaction at 12 weeks tended to be higher with heavy slow resistance (100 percent versus 80 percent, a difference that did not reach statistical significance), and training-session adherence was significantly better (92 percent versus 78 percent). In plain terms, in this trial ordinary strength work that people actually complete did about as well as the more specialized protocol. Our post on eccentric training and the lowering phase explains why that part of the lift gets so much attention.

You also do not have to stop training. A 2012 systematic review of seven randomized trials in patellar tendinopathy (Saithna et al., Open Orthopaedics Journal) found no high-quality evidence supporting withdrawal from sport during rehab. Only one of those trials, Kongsgaard et al., set a pain limit for continuing sport (a pain score below 30 out of 100 during activity), borrowing the idea from Achilles research that had used a limit of 50. The review also rated the evidence as low quality: no trial scored above 3 out of 5 on the Jadad quality scale, most were likely underpowered, and follow-up was short. Treat those limits as a research starting point rather than a prescription.

Here is an illustrative structure to take to your physical therapist, not a program to self-prescribe:

Choose one loaded movement that reproduces your symptoms mildly and predictably, such as a standing calf raise for the Achilles or a leg press or leg extension for the patellar tendon.
Train it two or three non-consecutive days a week, for three or four sets of slow reps, around three seconds up and three seconds down.
Rate pain from 0 to 10 during the set and note how the area feels the next morning. How much discomfort is acceptable is a call for your clinician, not a number to borrow from a blog. If pain climbs or the next day is worse, reduce the load or shorten the range and tell your clinician.
Add weight in the smallest steps your equipment allows, only after the current load felt manageable for two sessions in a row.
Plan in months. The trials above ran 12 weeks before anyone judged the result.

3. Manage the weekly load

Tendons often complain after a spike: a new exercise, a jump in volume, a return from time off. Keep the rest of your training steady, and use a planned deload week instead of grinding through. If one limb is out of action, training the other side can help you stay strong.

4. Keep the basics boring

Sleep, enough food and protein, and steady progression are the basics to get right before adding any product. Our ranking of recovery methods sorts popular options by evidence, and the piece on training as injury prevention covers how sensible loading protects joints and tendons. If you are curious about joint supplements, the collagen guide lays out what is and is not known. Ask a clinician first and favor independently tested products.

5. Track the trend

A loading plan only works if you can see the trend. In Easy Reps you can open any past session to see every set, filter your history by exercise or muscle group, and use the charts and calendar to spot stalls. For pain, jot your 0 to 10 rating beside the date in any notes app and compare the two over a few weeks.

Red flags and who this advice does not fit

Get examined before you follow any self-managed plan if you have any of the following:

A sudden pop or snap with immediate weakness, or inability to push off or bear weight.
Significant swelling, bruising or a visible deformity.
A joint that locks, gives way, or is hot, red and swollen, especially with a fever.
Numbness, tingling or weakness spreading into a limb.
Constant severe pain, or pain that wakes you at night.
Pain that started after a fall, a crash or another injury.
Pain, warmth and swelling in one calf.

The loading approach above also does not apply to suspected tears, recent surgery on that area (follow your surgeon's protocol), inflammatory arthritis, or growth-plate pain in teenagers. A clinician should decide on diagnosis, imaging, injections, surgery referral and whether any off-label treatment makes sense for your case.

If you have already used a peptide, tell your clinician. The AOSSM article advises sports-medicine physicians to ask patients about peptides and to discuss anti-doping consequences. Seek emergency care for hives, swelling of the lips, face or throat, wheezing or trouble breathing, fainting, or a racing heartbeat after any injection, and urgent care for spreading redness, pus or fever near an injection site.

Common mistakes

Treating a rat result as proof. Animal data justify trials. They do not tell you what a product does in you.
Resting completely for months. The patellar tendon review above found no high-quality evidence supporting withdrawal from sport. Ask your clinician how much to modify training rather than stopping outright.
Changing five things at once. If you swap exercises, loads and supplements together, you never learn what helped.

Bottom line

BPC-157 is an interesting laboratory peptide with a thin human evidence base, unresolved safety questions, an unclear legal path and a ban in tested sport. The 2026 committee vote changed the paperwork discussion, not the evidence. For a sore tendon or joint, get a diagnosis, load it progressively, manage your weekly volume and track the results. Talk to a clinician before considering anything else.